178 related articles for article (PubMed ID: 36944332)
21. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
[TBL] [Abstract][Full Text] [Related]
22. Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts.
Moura PL; Mortera-Blanco T; Hofman IJ; Todisco G; Kretzschmar WW; Björklund AC; Creignou M; Hagemann-Jensen M; Ziegenhain C; Cabrerizo Granados D; Barbosa I; Walldin G; Jansson M; Ashley N; Mead AJ; Lundin V; Dimitriou M; Yoshizato T; Woll PS; Ogawa S; Sandberg R; Jacobsen SEW; Hellström-Lindberg E
Cancer Res; 2024 Jan; 84(2):211-225. PubMed ID: 37921711
[TBL] [Abstract][Full Text] [Related]
23. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.
Dolatshad H; Pellagatti A; Liberante FG; Llorian M; Repapi E; Steeples V; Roy S; Scifo L; Armstrong RN; Shaw J; Yip BH; Killick S; Kušec R; Taylor S; Mills KI; Savage KI; Smith CW; Boultwood J
Leukemia; 2016 Dec; 30(12):2322-2331. PubMed ID: 27211273
[TBL] [Abstract][Full Text] [Related]
24. Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B1.
Trsova I; Hrustincova A; Krejcik Z; Kundrat D; Holoubek A; Staflova K; Janstova L; Vanikova S; Szikszai K; Klema J; Rysavy P; Belickova M; Kaisrlikova M; Vesela J; Cermak J; Jonasova A; Dostal J; Fric J; Musil J; Dostalova Merkerova M
Mol Oncol; 2023 Dec; 17(12):2565-2583. PubMed ID: 37408496
[TBL] [Abstract][Full Text] [Related]
25. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors.
Je EM; Yoo NJ; Kim YJ; Kim MS; Lee SH
Int J Cancer; 2013 Jul; 133(1):260-5. PubMed ID: 23280334
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis.
Jafari PA; Sadeghian MH; Miri HH; Sadeghi R; Bagheri R; Lavasani S; Souri S
Crit Rev Oncol Hematol; 2020 Jan; 145():102832. PubMed ID: 31812130
[TBL] [Abstract][Full Text] [Related]
27. Somatic
Foy A; McMullin MF
J Clin Pathol; 2019 Nov; 72(11):778-782. PubMed ID: 31473630
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
[TBL] [Abstract][Full Text] [Related]
29. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Pellagatti A; Boultwood J
Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
[TBL] [Abstract][Full Text] [Related]
30. MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells.
Pollyea DA; Kim HM; Stevens BM; Lee FF; Harris C; Hedin BR; Knapp JR; O'Connor BP; Jordan CT; Pietras EM; Tan AC; Alper S
J Leukoc Biol; 2021 Jul; 110(1):197-205. PubMed ID: 33155727
[TBL] [Abstract][Full Text] [Related]
31. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.
Visconte V; Rogers HJ; Singh J; Barnard J; Bupathi M; Traina F; McMahon J; Makishima H; Szpurka H; Jankowska A; Jerez A; Sekeres MA; Saunthararajah Y; Advani AS; Copelan E; Koseki H; Isono K; Padgett RA; Osman S; Koide K; O'Keefe C; Maciejewski JP; Tiu RV
Blood; 2012 Oct; 120(16):3173-86. PubMed ID: 22826563
[TBL] [Abstract][Full Text] [Related]
32. Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures.
Jenkins JL; Kielkopf CL
Trends Genet; 2017 May; 33(5):336-348. PubMed ID: 28372848
[TBL] [Abstract][Full Text] [Related]
33. Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis.
Wang X; Song X; Yan X
Medicine (Baltimore); 2019 May; 98(21):e15743. PubMed ID: 31124956
[TBL] [Abstract][Full Text] [Related]
34. [Mutational analysis of RNA splicing machinery genes SF3B1, U2AF1 and SRSF2 in 118 patients with myelodysplastic syndromes and related diseases].
Wang JY; Ma J; Lin YN; Wang J; Shen H; Gui FM; Han C; Li QH; Song Z; Wang XJ
Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):192-197. PubMed ID: 28395441
[No Abstract] [Full Text] [Related]
35. Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators.
Qiu J; Zhou B; Thol F; Zhou Y; Chen L; Shao C; DeBoever C; Hou J; Li H; Chaturvedi A; Ganser A; Bejar R; Zhang DE; Fu XD; Heuser M
RNA; 2016 Oct; 22(10):1535-49. PubMed ID: 27492256
[TBL] [Abstract][Full Text] [Related]
36. Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML.
Wheeler EC; Martin BJE; Doyle WC; Neaher S; Conway CA; Pitton CN; Gorelov RA; Donahue M; Jann JC; Abdel-Wahab O; Taylor J; Seiler M; Buonamici S; Pikman Y; Garcia JS; Belizaire R; Adelman K; Tothova Z
Sci Transl Med; 2024 Jan; 16(728):eade2774. PubMed ID: 38170787
[TBL] [Abstract][Full Text] [Related]
37. SF3b1 mutations associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeast.
Carrocci TJ; Zoerner DM; Paulson JC; Hoskins AA
Nucleic Acids Res; 2017 May; 45(8):4837-4852. PubMed ID: 28062854
[TBL] [Abstract][Full Text] [Related]
38. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
[TBL] [Abstract][Full Text] [Related]
39. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms.
Cazzola M; Rossi M; Malcovati L;
Blood; 2013 Jan; 121(2):260-9. PubMed ID: 23160465
[TBL] [Abstract][Full Text] [Related]
40. Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.
Venable ER; Chen D; Chen CP; Bessonen KR; Nguyen PL; Oliveira JL; Reichard KK; Hoyer JD; Althoff SD; Roh DJ; Miller MA; Begna K; Patnaik MM; Litzow MR; Al-Kali A; Viswanatha DS; He R
Am J Clin Pathol; 2021 Sep; 156(4):679-690. PubMed ID: 33978189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
